PDF(Pubmed)
Abstract：
Corpus Atrophic Gastritis (CAG) is characterised by iron malabsorption leading to iron deficiency anaemia (IDA), which rarely responds to oral therapy. Ferric carboxymaltose (FCM), shown to be a safe and effective intravenous iron therapy in other diseases, has not been investigated yet in CAG. Thus, we aimed to assess the safety and efficacy of FCM in CAG-related IDA. A retrospective study on 91 patients identified CAG as the only cause of IDA treated with FCM. Twenty-three were excluded for incomplete follow-up. Sixty-eight were evaluated for safety and efficacy, while three were evaluated for safety only due to infusion interruption for side effects. Haemoglobin and iron storage were evaluated pre-infusion (T0), at 4 weeks (T4) and 12 weeks (T12) after infusion. An eventual IDA relapse was analysed. Two cases reported mild side effects. Haemoglobin significantly increased at T4, and T12, reaching +3.1 g/dL. Ferritin increased at T4, decreasing at T12, while transferrin saturation increased progressively until reaching a plateau. IDA relapsed in 55.4% of patients at a mean of 24.6 months. The only factor associated with relapse was female gender [OR (95% CI): 6.6 (1.5-28.6)]. FCM proved to be safe and effective in treating CAG-related IDA, ensuring quick and long-lasting recovery.
摘要：
萎缩性胃炎（CAG）的特征是铁吸收不良导致缺铁性贫血（IDA），很少对口服治疗有反应。羧基麦芽糖铁（FCM），在其他疾病中被证明是安全有效的静脉铁疗法，尚未在CAG中进行调查。因此，我们旨在评估FCM在CAG相关IDA中的安全性和有效性.一项针对91例患者的回顾性研究确定CAG是FCM治疗IDA的唯一原因。23例因不完全随访而被排除在外。对68人进行了安全性和有效性评估，而3例仅因因副作用中断输注而进行了安全性评估。输注前（T0）评估血红蛋白和铁的储存，在输注后4周（T4）和12周（T12）。分析了最终的IDA复发。2例报告轻度副作用。血红蛋白在T4和T12时显著增加,达到+3.1g/dL。铁蛋白在T4时增加，在T12时减少，而转铁蛋白饱和度逐渐增加，直到达到平稳状态。55.4%的患者在平均24.6个月时IDA复发。与复发相关的唯一因素是女性[OR（95％CI）：6.6（1.5-28.6）]。FCM被证明是安全有效的治疗CAG相关的IDA，确保快速和持久的恢复。
